On To Phase II Trials For JAK2, Singapore's S*BIO Reports
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Singapore-based biotech S*BIO reported positive data on its Phase I trials for its Janus kinase 2 inhibitor SB1518 at the American Society of Hematology annual meeting in New Orleans Dec. 7
You may also be interested in...
Singapore's S*BIO Expands Collaboration With Onyx On JAK2 Inhibitors
PERTH, Australia - Singapore-based S*BIO and U.S.-based Onyx Pharmaceuticals are expanding their development collaboration to include additional indications for S*BIO's novel JAK2 inhibitors, the companies announced May 4
Singapore's S*BIO Expands Collaboration With Onyx On JAK2 Inhibitors
PERTH, Australia - Singapore-based S*BIO and U.S.-based Onyx Pharmaceuticals are expanding their development collaboration to include additional indications for S*BIO's novel JAK2 inhibitors, the companies announced May 4
S*BIO Collaborates With Singapore Hospital To Explore JAK2 Inhibitor Pathway
PERTH, Australia - Singapore-based S*BIO signed a collaboration agreement with Tan Tock Seng Hospital in Singapore to evaluate therapeutic effects of its JAK2 inhibitor SB1518 on biological samples from patients with myeloproliferative neoplasms, S*BIO announced Dec. 19